Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:15 PM
Ignite Modification Date:
2025-12-24 @ 2:15 PM
NCT ID:
NCT00105495
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of thalassemia major as confirmed by laboratory and clinical criteria
* Participants who are well transfused-maintaining a mean pre-transfusion Hb (hemoglobin) no less than 9 g/dL.
* Between 18 and 36 years of age.
* Receiving ongoing chelation therapy with deferoxamine for at least the past five years. Those who have been exposed to deferiprone for
≤ 6 months but not within the last 2 years prior to commencement of this study will be considered eligible to participate.
* Abnormal heart MRI T2\* greater than or equal to 8 ms and \< 20 ms.
* If female, fertile, and is neither pregnant nor lactating, confirms she will use an effective method of contraception for the length of the trial and has a negative pregnancy test immediately prior to commencement of study drug OR has had a tubal ligation OR a hysterectomy OR is post menopausal (at least 1 year no menses prior to enrollment in the study) OR their only sexual partner has been sterilized (if male).
* If male and fertile, he confirms that he and/or his partner will use an effective method of contraception for the length of the trial.
* Provide a signed and witnessed written informed consent obtained prior to the first study intervention.
Exclusion Criteria:
* Have anemia other than thalassemia.
* HIV antibody positive.
* Clinical evidence of cardiomyopathy as shown by LV Shortening Fraction \< 30 % and/or CMR derived LV (left ventricular) Ejection Fraction \< 56 %.
* Severe/significant arrhythmia, including those who have had atrial fibrillation (participants with occasional ectopic beats and normal echo can be included) or those requiring treatment.
* Previously discontinued therapy with deferiprone or deferoxamine because of an adverse drug reaction to either chelator.
* Have received deferiprone in the last five years. However those who have been exposed to deferiprone for ≤ 6 months but not within the last 2 years prior to commencement of this study will be considered eligible to participate.
* Evidence of abnormal liver function (liver enzymes \> 3 times upper limit of normal - entry may be delayed until return to normal).
* Have disorders associated with neutropenia (ANC \< 1.5 x 10\^9/L) or thrombocytopenia (platelet count \<50 x 10\^9/L) in the twelve months prior to start of study medication, except for participants who have been treated with interferon and in whom the ANC has fully recovered. Participants with neutropenia or thrombocytopenia in the last year, which resolved with splenectomy, may be considered for this study.
* Those who refuse to participate in the screening procedures or who are unable to participate in screening procedures or who are unable to comply with requirements of the protocol.
* Receiving other investigational products.
* Those in the opinion of the Investigator, who represent poor medical, psychological or psychiatric risks for whom participation in an investigational trial would be unwise.
* Those who are pregnant, breastfeeding or planning to become pregnant during the study period.
* Metallic objects in his/her body, such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas.
* History of malignancy.
* Participants with claustrophobia.
* History of alcohol or drug abuse.
* Participants who are, in the opinion of the Investigator, excessively obese.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
36 Years
Study:
NCT00105495
Study Brief:
Protocol Section:
NCT00105495